Company & Sponsor Intelligence
Yonsei University
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed3
Countries1
Therapeutic footprint
epilepsysleep_disordersstroke
Indexed studies
NCT06339853Study of Efficacy of Digital Cognitive Behavioral Therapy With Wearable Device for Insomnia
sleep_disorders · South KoreaNA
sleep_disorders · South KoreaNA
NCT03198949A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)
epilepsy · South KoreaPHASE2
epilepsy · South KoreaPHASE2
NCT02964052Selection Criteria in Endovascular Thrombectomy and Thrombolytic Therapy (SECRET) Study: Development of Patient Selection Criteria Using CT Images and Accompanying Diseases for Efficient Intravenous Thrombolytic and Intra-arterial Recanalization Therapy in Acute Ischemic Stroke
stroke · South KoreaCOMPLETED
stroke · South KoreaCOMPLETED
Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →